Phase IV Study to Test PCV15 Vaccine Protection Against Pneumococcal Type 3 Colonisation in Healthy Adults Aged 18 to 50 in the UK
Led by University of Oxford · Updated on 2025-04-15
106
Participants Needed
2
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the PCV15 vaccine to see if it can protect healthy adults aged 18 to 50 from carrying Streptococcus pneumoniae bacteria in their noses, which can lead to serious pneumonia in vulnerable people. This Phase IV double-blind study compares PCV15 with a placebo by exposing participants to a controlled amount of pneumococcus bacteria after vaccination to assess how well the vaccine prevents colonization.
Participants will be randomly assigned to receive either one dose of PCV15 or a saline placebo injection. One month after vaccination, all participants will have a small amount of pneumococcus bacteria introduced into their noses. They will be closely monitored in the clinic for 28 days to assess bacterial colonization and immune responses, then take a 5-day course of antibiotics to clear the bacteria. A small group will undergo nasal biopsies to study immune reactions but will not receive the bacteria challenge.
Throughout the study, participants will attend scheduled visits for lab tests, immune response assessments, and monitoring of bacterial presence on days 2, 7, 14, and 28 after bacterial exposure. Safety is carefully managed with regular check-ups, and participants who meet criteria will receive antibiotic treatment after the challenge. The entire study lasts about two months, including vaccination, bacterial challenge, follow-up, and antibiotic treatment.
CONDITIONS
Brief Title
Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15
Research Team
C
Carla Solorzano-Gonzalez, PhD
S
Simon Drysdale
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Significant uncontrolled medical, surgical, or mental health conditions
Major pneumococcal illness requiring hospitalization in last 10 years
Use of immune-affecting medications in last 3 months
Long-term antibiotic use or nasal medication use in past month
Use of blood clotting medications
Pregnant, lactating, or planning pregnancy during study
Close contact with high-risk individuals such as young children, chronically ill, or older adults
Current or recent smoker within 6 months or heavy smoking history
Suspected or known alcohol or drug abuse
Overseas travel during follow-up period
Any other condition that may risk participant or affect study results
Study site staff or their close family members
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 1 month until inoculation
Participants are randomly assigned to receive either the PCV15 vaccine or a placebo by intramuscular injection. One month after vaccination, participants are intranasally inoculated with Streptococcus pneumoniae serotype 3.
1 vaccination visit and 1 inoculation visit
Follow-up
Duration - 28 days
Participants are monitored for 28 days after inoculation with assessment of nasal pneumococcal colonisation and immune response, followed by a 5-day course of antibiotics.
Visits on Days 2, 7, 14, and 28 following inoculation
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Phase 3 Trial to Test Safety and Immune Response of 23-valent Pneumococcal Vaccine in Healthy People Aged 2 Years and Older
Evaluating Safety and Immune Response of Three Lots of a New Multivalent Pneumococcal Conjugate Vaccine Compared to 20vPnC in Adults 18 to 49 Years
Evaluating Safety and Immune Response of a New Pneumococcal Vaccine Compared to Current Vaccine in Healthy Infants
Evaluating the Safety and Tolerability of a New Multivalent Pneumococcal Vaccine Compared to the 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants
Phase IV Study to Test PCV15 Vaccine Protection Against Pneumococcal Type 3 Colonisation in Healthy Adults Aged 18 to 50 in the UK
Evaluating New Pneumococcal Conjugate Vaccines PCV20 and PCV21 for Antibody Protection Against Serogroup 33 in Adults
Immune Response to Pneumosil Versus Typhoid Conjugate Vaccine in Children 6-59 Months Hospitalized with Severe Acute Malnutrition A Randomized Controlled Trial
Study of How Long Streptococcus Pneumoniae Bacteria Stay in the Nose and Throat of Children Under 4 Years in the U.S.
Study of Pneumococcal Bacteria Carriage in Children and Adults After the Pandemic
Genomic Analysis and Comparison of Pneumococcal Strains in a US City
Phase 1B Study to Collect Serum After Vaccination with Gamma-PN Pneumococcal Vaccine in Adults for Assay Testing
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Protocol for a phase IV, Experimental Human Pneumococcal Challenge (EHPC) model to investigate Streptococcus pneumoniae serotype 3 (SPN3) colonisation following PCV15, a double-blind randomised controlled trial in healthy participants aged 18-50 years in the UK (RATIONALE-15).
Bruno Rocha de Macedo, Carla Solórzano, Angela Hyder-Wright...